ENDRA Life Sciences Inc. and VGI Health Technology Limited announce the signing of a collaboration agreement to incorporate ENDRA's proprietary TAEUS technology to support patient screening and biomarker measurement during VGI's upcoming Phase 2 study of IVB001 in Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH).
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.02 AUD | -33.33% | -.--% | -.--% |
1st Jan change | Capi. | |
---|---|---|
-.--% | 1.81M | |
-3.18% | 102B | |
+1.63% | 96.29B | |
+2.13% | 22.18B | |
-15.60% | 21.2B | |
-9.21% | 18.31B | |
-39.98% | 17.38B | |
-15.75% | 16.36B | |
+4.77% | 13.97B | |
+32.23% | 12.17B |
- Stock Market
- Equities
- VTL Stock
- News VGI Health Technology Limited
- ENDRA Life Sciences Expands Pharmaceutical Partnerships with VGI Health Technology to Provide TAEUS for Patient Screening and Biomarker Measurement for Phase 2 Study